Literature DB >> 22495174

DRD1 associations with smoking abstinence across slow and normal nicotine metabolizers.

Wonho Lee1, Riju Ray, Andrew W Bergen, Gary E Swan, Paul Thomas, Rachel F Tyndale, Neal L Benowitz, Caryn Lerman, David V Conti.   

Abstract

Nicotine metabolism and genetic variation have an impact on nicotine addiction and smoking abstinence; however, further research is required. The nicotine metabolite ratio (NMR) is a robust biomarker of nicotine metabolism used to categorize slow and normal nicotine metabolizers (lower 25th quartile cut off). In two randomized clinical trials of smoking abstinence treatments, we conducted NMR-stratified analyses on smoking abstinence across 13 regions coding for nicotinic acetylcholine receptors and proteins involved in the dopamine reward system. Gene×NMR interaction P-values were adjusted for multiple correlated tests, and we used a Bonferroni-corrected α-level of 0.004 to determine system-wide significance. Three single-nucleotide polymorphisms in DRD1 (rs11746641, rs2168631, and rs11749035) had significant interactions (0.001 ≤ adjusted P-values ≤ 0.004) with increased odds of abstinence within slow metabolizers (odds ratios=3.1-3.5, 95% confidence interval 1.7-6.7). Our findings support the role of DRD1 in nicotine dependence, and identify genetic and nicotine metabolism profiles that may interact to impact nicotine dependence.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22495174      PMCID: PMC3376177          DOI: 10.1097/FPC.0b013e3283539062

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  14 in total

1.  Biochemical verification of tobacco use and cessation.

Authors: 
Journal:  Nicotine Tob Res       Date:  2002-05       Impact factor: 4.244

2.  Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.

Authors:  Delia Dempsey; Piotr Tutka; Peyton Jacob; Faith Allen; Kerri Schoedel; Rachel F Tyndale; Neal L Benowitz
Journal:  Clin Pharmacol Ther       Date:  2004-07       Impact factor: 6.875

Review 3.  Nicotinic acetylcholine receptors and the ascending dopamine pathways.

Authors:  Phil D Livingstone; Susan Wonnacott
Journal:  Biochem Pharmacol       Date:  2009-06-11       Impact factor: 5.858

4.  Association of the nicotine metabolite ratio and CHRNA5/CHRNA3 polymorphisms with smoking rate among treatment-seeking smokers.

Authors:  Mary Falcone; Christopher Jepson; Neal Benowitz; Andrew W Bergen; Angela Pinto; E Paul Wileyto; Don Baldwin; Rachel F Tyndale; Caryn Lerman; Riju Ray
Journal:  Nicotine Tob Res       Date:  2011-03-08       Impact factor: 4.244

5.  Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk.

Authors:  Catherine A Wassenaar; Qiong Dong; Qingyi Wei; Christopher I Amos; Margaret R Spitz; Rachel F Tyndale
Journal:  J Natl Cancer Inst       Date:  2011-07-11       Impact factor: 13.506

6.  Dopamine D1 and D2 receptor mRNA up-regulation in the caudate-putamen and nucleus accumbens of rat brains by smoking.

Authors:  Jong Y Bahk; Shupeng Li; Moon S Park; Myeong O Kim
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2002-10       Impact factor: 5.067

7.  The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire.

Authors:  T F Heatherton; L T Kozlowski; R C Frecker; K O Fagerström
Journal:  Br J Addict       Date:  1991-09

8.  Significant association of DRD1 with nicotine dependence.

Authors:  Weihua Huang; Jennie Z Ma; Thomas J Payne; Joke Beuten; Randolph T Dupont; Ming D Li
Journal:  Hum Genet       Date:  2007-12-19       Impact factor: 4.132

9.  Association of nicotine addiction and nicotine's actions with separate cingulate cortex functional circuits.

Authors:  L Elliot Hong; Hong Gu; Yihong Yang; Thomas J Ross; Betty Jo Salmeron; Brittany Buchholz; Gunvant K Thaker; Elliot A Stein
Journal:  Arch Gen Psychiatry       Date:  2009-04

10.  Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation.

Authors:  David V Conti; Won Lee; Dalin Li; Jinghua Liu; David Van Den Berg; Paul D Thomas; Andrew W Bergen; Gary E Swan; Rachel F Tyndale; Neal L Benowitz; Caryn Lerman
Journal:  Hum Mol Genet       Date:  2008-07-01       Impact factor: 6.150

View more
  6 in total

1.  Treatment for tobacco dependence: effect on brain nicotinic acetylcholine receptor density.

Authors:  Arthur L Brody; Alexey G Mukhin; Michael S Mamoun; Maggie Kozman; Jonathan Phuong; Meaghan Neary; Trinh Luu; Mark A Mandelkern
Journal:  Neuropsychopharmacology       Date:  2013-02-21       Impact factor: 7.853

Review 2.  Biomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date.

Authors:  Michael Mamoun; Andrew W Bergen; Jennifer Shieh; Anna Wiggins; Arthur L Brody
Journal:  CNS Drugs       Date:  2015-05       Impact factor: 5.749

Review 3.  New mechanisms and perspectives in nicotine withdrawal.

Authors:  K J Jackson; P P Muldoon; M De Biasi; M I Damaj
Journal:  Neuropharmacology       Date:  2014-11-26       Impact factor: 5.250

4.  The dopamine receptor D1 gene is associated with the length of interval between first heroin use and onset of dependence in Chinese Han heroin addicts.

Authors:  Sufang Peng; Jiang Du; Haifeng Jiang; Yingmei Fu; Hanhui Chen; Haiming Sun; Dongxiang Wang; Shunying Yu; Min Zhao
Journal:  J Neural Transm (Vienna)       Date:  2013-05-10       Impact factor: 3.575

5.  The Twin Research Registry at SRI International.

Authors:  Ruth E Krasnow; Lisa M Jack; Christina N Lessov-Schlaggar; Andrew W Bergen; Gary E Swan
Journal:  Twin Res Hum Genet       Date:  2012-10-19       Impact factor: 1.587

Review 6.  Pharmacotherapy for smoking cessation: effects by subgroup defined by genetically informed biomarkers.

Authors:  Ewoud Schuit; Orestis A Panagiotou; Marcus R Munafò; Derrick A Bennett; Andrew W Bergen; Sean P David
Journal:  Cochrane Database Syst Rev       Date:  2017-09-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.